Antiandrojenler
Özet
Androjen deprivasyon tedavisi (ADT), metastatik veya yüksek riskli lokalize prostat kanseri tedavisinin temelini oluşturmaktadır. Bu tedavinin temel amacı, serum testosteron düzeyini kastrasyon seviyesine düşürerek kanser hücrelerinin büyümesini engellemektir. Geleneksel olarak kullanılan LHRH agonistleri, tedavinin başlangıcında testosteron seviyelerinde geçici bir artışa (alevlenme fenomeni) yol açarken, yeni nesil Gonadotropin Salgılayan Hormon (GnRH) antagonistleri bu olumsuz duruma neden olmadan testosteronu doğrudan ve hızla baskılar. Üçüncü kuşak subkutan bir antagonist olan degarelix ve ilk oral GnRH antagonisti olan relugolix, bu gruptaki öne çıkan ajanlardır. Yapılan faz çalışmaları ve meta-analizler, GnRH antagonistlerinin LHRH agonistlerine kıyasla testosteron seviyelerini daha hızlı düşürdüğünü, alt üriner sistem semptomlarında belirgin bir iyileşme sağladığını ve PSA progresyonsuz sağkalım süresini uzattığını göstermiştir. Enjeksiyon bölgesi reaksiyonları antagonistlerde daha sık görülse de, bu ilaçların kas-iskelet sistemi ve özellikle kardiyovasküler yan etkiler açısından daha güvenli bir profile sahip olduğu saptanmıştır. Bu nedenle GnRH antagonistleri, özellikle eşlik eden kardiyovasküler komorbiditesi bulunan ileri evre prostat kanseri hastalarında klinik olarak daha güvenilir ve etkili bir tedavi seçeneği sunmaktadır.
Androgen deprivation therapy (ADT) serves as the cornerstone in managing metastatic or high-risk localized prostate cancer. The primary goal of ADT is to suppress serum testosterone to castration levels, thereby preventing the proliferation of androgen-dependent cancer cells. While traditional LHRH agonists induce a transient testosterone surge known as the flare phenomenon, gonadotropin-releasing hormone (GnRH) antagonists directly and rapidly inhibit gonadotropin production without causing this initial spike. Degarelix, a third-generation subcutaneous injection, and relugolix, the first approved oral GnRH antagonist, represent key advancements in this therapeutic class. Phase III clinical trials and subsequent meta-analyses demonstrate that GnRH antagonists achieve rapid testosterone suppression within days, significantly improve lower urinary tract symptoms, and extend prostate-specific antigen (PSA) progression-free survival compared to standard agonists. Although GnRH antagonists are associated with higher rates of local injection site reactions, they exhibit a superior safety profile regarding musculoskeletal issues and major adverse cardiovascular events. Consequently, GnRH antagonists constitute a highly effective and safer therapeutic alternative, particularly for advanced prostate cancer patients with pre-existing cardiovascular comorbidities.
Referanslar
Huggins, C.,Hodges, C.V., 1941. Studies on prostatic cancer. I. Theeffect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CancerRes. 1, 293–297.
Sutudent S et al. Anti-androgen hormonal therapy for cancer and other disease. Eu j of Pharma, 2020, 866, 172873.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
Cornford, P.,Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., Henry, A.M., Joniau, S., Lam, T.B., Mason, M.D., van der Poel, H.G., van der Kwast, T.H., Rouvière, O., Wiegel, T., Mottet, N., 2017. EAU-ESTRO-SIOG guidelines on prostatecancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur. Urol. 71, 630–642.
SEER*Explorer: an interactive web site for SEER cancer statistics. Surveillance Research Program. https://seer.cancer.gov. Accessed February 14, 2021.
Desai K et al. Hormonal therapy for prostate cancer. EndocrRev, 2021. 42(3): 354-373.
Matsumoto T, Sakari M, Okada M, et al. The androgen receptor in health and disease. Annu Rev Physiol. 2013;75:201-224.
Brawer, M.K., 2006. Hormonal therapy for prostate cancer. Rev. Urol. 8, 35–47.
Crawford et al. Androgen receptor targeted treatments of prostate cancer: 35 years of progress with antiandrogenes. J Urol 2018. 200(5):956-966.
Pavone-Macaluso M, de Voogt HJ, Viggiano G et al: Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesteroneacetate in the treatment of advanced prostatic cancer: final analysis of a randomize dphase III trial of the Europe an Organization for Research on Treatment of Cancer Urological Group. J Urol 1986; 136: 624.
Neri R: Pharmacology and pharmacokinetics of flutamide. Urology 1989; 34: 19.
Plante M, Lapointe S andLabrie F: Stimulatoryeffect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. J Steroid Biochem 1988; 31: 61.
Neri R: Pharmacology and pharmacokinetics of flutamide. Urology 1989; 34: 19.
Baker JW, Bachman GL, Schumacher I et al: Synthesis and bacteriostatic activity of some nitrotrifluoromethylanilides. J MedChem 1967; 10: 93.
Crawford ED, Eisenberger MA, McLeod DG et al: A controlled trial of leuprolide with and with out flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419.
Eisenberger MA, Blumenstein BA, Crawford ED et al: Bilateral orchiectomy with or without flutamide for metastatic prostatecancer. N Engl J Med 1998; 339: 1036.
Ornstein DK, Beiser JA andAndriole GL: Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer. BJU Int 1999; 83: 43.
Debruyne: nilutamide, Debruyne FM: EurUrol, suppl, 1996; 30
Bennett: flutamide, Bennett CL: Prostate Cancer Prostatic Dis 1999; 2
Boccardo F, Decensi AU, Guarneri D et al: Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multi centric Italian study. Cancer Detect Prev 1991; 15: 501.
Decensi AU, Boccardo F, Guarneri D et al: Mono therapy with nilutamide, a pure non steroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol 1991; 146: 377
Iversen P, Tyrrell CJ, Kaisary AV et al: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol 2000; 164: 1579.
Tyrrell CJ, Kaisary AV, Iversen P et al: A randomised comparison of ’Casodex’ (bicalutamide) 150 mg mono therapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447.
Iversen P, McLeod DG, See WA et al: Antiandrogen mono therapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int 2010; 105: 1074.
Labrie F, Dupont A and Belanger A: Complete androgen blockade for the treatment of prostate cancer. In: Important Advances in Oncology 1985. Edited by VT DeVitaJr, S Hellmanand SA Rosenberg. Philadelphia: Lippincott Williams &Wilkins 1985; pp 193e217.
